Clinical Oncology Next Generation Sequencing (NGS) is an advanced genomic technology used to analyze the genetic makeup of cancer cells. NGS allows for comprehensive analysis of various genetic variants, including single-nucleotide variations (SNVs), insertions, deletions, exon duplications, gene copy number changes, and translocations. The key advantage of NGS lies in its ability to analyze large volumes of genetic data quickly and accurately, providing valuable insights into cancer's molecular mechanisms, enabling better diagnosis, prognosis, and treatment decisions. This technology is a key component in personalized cancer therapy, offering the potential for more targeted and effective treatments based on an individual’s unique genetic profile.
Market Size
The global Clinical Oncology Next Generation Sequencing (NGS) market is on a robust growth trajectory. As of 2024, the market was valued at USD 704.70 million and is forecasted to reach USD 1577.78 million by 2032. This represents a compound annual growth rate (CAGR) of 10.60% over the forecast period.
The increasing prevalence of cancer, the rise in personalized medicine, and advancements in sequencing technology are key drivers of this growth.
The market’s growth is further fueled by the adoption of NGS in both academic and clinical research settings, as well as its expanding use in hospitals and clinics for diagnostics and treatment planning. The rise of affordable sequencing platforms, the increasing availability of genomic data, and the development of bioinformatics tools are also propelling the market forward.
Market Dynamics
Drivers
-
Rising Cancer Incidence: The increasing global incidence of cancer is one of the primary factors driving the demand for advanced diagnostic tools such as NGS. According to the World Health Organization, cancer is the second leading cause of death worldwide, necessitating advanced methods like NGS for early detection and precise treatment.
-
Personalized Medicine Growth: There is a growing shift toward personalized medicine, where treatments are tailored to the genetic makeup of individuals. NGS plays a crucial role in identifying mutations and biomarkers that influence treatment decisions, enhancing the effectiveness of therapies and reducing side effects.
-
Technological Advancements: Ongoing innovations in NGS technology, including improvements in sequencing accuracy, speed, and cost-effectiveness, are significantly contributing to the market growth. The introduction of more affordable and portable sequencing platforms is opening up new opportunities in both clinical and research settings.
Restraints
-
High Costs of NGS Platforms: Despite advancements, the initial cost of NGS platforms and the required infrastructure for data analysis remain significant barriers, particularly for smaller healthcare providers in emerging markets.
-
Data Analysis Complexity: The vast amount of data generated by NGS can be overwhelming. Analyzing and interpreting these data requires sophisticated bioinformatics tools and expertise, posing a challenge to many healthcare providers and researchers.
-
Regulatory Challenges: The regulatory environment surrounding the use of NGS for clinical purposes is still evolving. Variability in regulations across regions can slow down the adoption of these technologies in clinical settings.
Opportunities
-
Emerging Markets: There is significant potential for market growth in emerging economies where the healthcare infrastructure is expanding, and the awareness of genetic testing is increasing. As these markets adopt advanced healthcare technologies, NGS will play an essential role in improving cancer care.
-
Partnerships and Collaborations: Strategic collaborations between technology companies, healthcare providers, and research institutions to develop more affordable and accessible NGS solutions present significant growth opportunities. Partnerships could also drive innovation in the development of new diagnostic and therapeutic solutions.
-
Integration with AI and Machine Learning: The integration of artificial intelligence (AI) and machine learning (ML) with NGS technologies offers the potential for faster and more accurate data interpretation, creating new avenues for clinical applications and personalized treatment plans.
Challenges
-
Data Privacy and Security Concerns: With the growing use of genomic data in healthcare, there are concerns about patient privacy and data security. Regulatory bodies are increasingly focusing on data protection laws, adding complexity to the widespread adoption of NGS technologies.
-
Technical Skill Shortage: There is a shortage of skilled professionals in bioinformatics and genomics, which could hinder the ability to fully capitalize on the potential of NGS technology in clinical settings.
Regional Analysis
North America
North America is expected to dominate the Clinical Oncology NGS market due to the high healthcare spending, advanced medical infrastructure, and early adoption of new technologies. In 2024, the North American market size was estimated at USD 218.51 million, with a projected CAGR of 9.09% during the forecast period. The U.S. is the largest contributor, with significant investments in cancer research and a high demand for precision medicine.
Europe
Europe holds a significant share of the global market, driven by the growing emphasis on personalized medicine and cancer genomics. Countries such as Germany, the U.K., and France are at the forefront of NGS research and clinical applications. However, the market's growth rate is slightly slower compared to North America due to regulatory complexities and varied adoption across countries.
Asia-Pacific
The Asia-Pacific region is anticipated to witness the highest growth rate over the forecast period. Countries like China, Japan, and India are investing heavily in healthcare infrastructure and research. The expanding middle class, increasing cancer incidence, and greater access to healthcare services are key drivers in this region.
South America and Middle East & Africa
While these regions represent a smaller share of the market, there is significant growth potential, particularly with the increasing focus on healthcare modernization and rising awareness about genetic testing.
Competitor Analysis
Key players in the Clinical Oncology NGS market include Illumina, Roche, Agilent Technologies, and Oxford Nanopore Technologies. These companies are focused on innovation, product development, and strategic collaborations to maintain their competitive edge. Illumina, for example, is a leading player, known for its cutting-edge sequencing technologies, while Roche has been investing in oncology-focused genomic solutions. Smaller players like Genomatix Software and GATC Biotech also contribute to the competitive landscape with specialized offerings.
Global Clinical Oncology Next Generation Sequencing (NGS): Market Segmentation Analysis
This report provides a deep insight into the global Clinical Oncology Next Generation Sequencing (NGS) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and assessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Clinical Oncology Next Generation Sequencing (NGS) Market. This report introduces in detail the market share, market performance, product situation, operation situation, etc., of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Clinical Oncology Next Generation Sequencing (NGS) market in any manner.
Market Segmentation (by Application)
- Academic & Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
Market Segmentation (by Type)
- NGS Pre-Sequencing
- Sequencing
- NGS Data Analysis
- Primary, Secondary & Tertiary Data Analysis
Key Company
- Illumina
- Roche
- Agilent Technologies
- Knome
- Genomatix Software
- GATC Biotech
- Oxford Nanopore Technologies
- Macrogen
- Life Technologies
- DNASTAR
- Exosome Diagnostics
- Biomatters
- CLC Bio
- BGI
- Qiagen
- Perkin Elmer
- Pacific Bioscience
- Partek
- GnuBIO
- Foundation Medicine
- Paradigm
- Caris Life Sciences
- Myriad Genetics
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
FAQ Section
What is the current market size of the Clinical Oncology NGS market?
- As of 2024, the market size is estimated at USD 704.70 million and is projected to grow to USD 1745.02 million by 2032.
Which are the key companies operating in the Clinical Oncology NGS market?
- Key players include Illumina, Roche, Agilent Technologies, and Oxford Nanopore Technologies.
What are the key growth drivers in the Clinical Oncology NGS market?
- Key drivers include the rising incidence of cancer, the growth of personalized medicine, and advancements in sequencing technology.
Which regions dominate the Clinical Oncology NGS market?
- North America dominates the market, followed by Europe and the Asia-Pacific region.
What are the emerging trends in the Clinical Oncology NGS market?
- Emerging trends include the integration of AI with NGS, increased investments in emerging markets, and the development of more affordable sequencing technologies.
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Clinical Oncology Next Generation Sequencing (NGS) Market
- Overview of the regional outlook of the Clinical Oncology Next Generation Sequencing (NGS) Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Clinical Oncology Next Generation Sequencing (NGS)
1.2 Key Market Segments
1.2.1 Clinical Oncology Next Generation Sequencing (NGS) Segment by Type
1.2.2 Clinical Oncology Next Generation Sequencing (NGS) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Clinical Oncology Next Generation Sequencing (NGS) Market Overview
2.1 Global Market Overview
2.1.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Clinical Oncology Next Generation Sequencing (NGS) Market Competitive Landscape
3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Manufacturers (2019-2025)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Manufacturers (2019-2025)
3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Clinical Oncology Next Generation Sequencing (NGS) Sales Sites, Area Served, Product Type
3.6 Clinical Oncology Next Generation Sequencing (NGS) Market Competitive Situation and Trends
3.6.1 Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Clinical Oncology Next Generation Sequencing (NGS) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Clinical Oncology Next Generation Sequencing (NGS) Industry Chain Analysis
4.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Clinical Oncology Next Generation Sequencing (NGS) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2019-2025)
6.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2019-2025)
6.4 Global Clinical Oncology Next Generation Sequencing (NGS) Price by Type (2019-2025)
7 Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Sales by Application (2019-2025)
7.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) by Application (2019-2025)
7.4 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Growth Rate by Application (2019-2025)
8 Clinical Oncology Next Generation Sequencing (NGS) Market Consumption by Region
8.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.1.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Region
8.2 North America
8.2.1 North America Clinical Oncology Next Generation Sequencing (NGS) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Clinical Oncology Next Generation Sequencing (NGS) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Clinical Oncology Next Generation Sequencing (NGS) Market Production by Region
9.1 Global Production of Clinical Oncology Next Generation Sequencing (NGS) by Region (2019-2025)
9.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Region (2019-2025)
9.3 Global Clinical Oncology Next Generation Sequencing (NGS) Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Clinical Oncology Next Generation Sequencing (NGS) Production
9.4.1 North America Clinical Oncology Next Generation Sequencing (NGS) Production Growth Rate (2019-2025)
9.4.2 North America Clinical Oncology Next Generation Sequencing (NGS) Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Clinical Oncology Next Generation Sequencing (NGS) Production
9.5.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Production Growth Rate (2019-2025)
9.5.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Clinical Oncology Next Generation Sequencing (NGS) Production (2019-2025)
9.6.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Production Growth Rate (2019-2025)
9.6.2 Japan Clinical Oncology Next Generation Sequencing (NGS) Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Clinical Oncology Next Generation Sequencing (NGS) Production (2019-2025)
9.7.1 China Clinical Oncology Next Generation Sequencing (NGS) Production Growth Rate (2019-2025)
9.7.2 China Clinical Oncology Next Generation Sequencing (NGS) Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Illumina
10.1.1 Illumina Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.1.2 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.1.4 Illumina Business Overview
10.1.5 Illumina Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
10.1.6 Illumina Recent Developments
10.2 Roche
10.2.1 Roche Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.2.2 Roche Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.2.4 Roche Business Overview
10.2.5 Roche Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
10.2.6 Roche Recent Developments
10.3 Agilent Technologies
10.3.1 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.3.2 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.3.4 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
10.3.5 Agilent Technologies Business Overview
10.3.6 Agilent Technologies Recent Developments
10.4 Knome
10.4.1 Knome Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.4.2 Knome Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.4.4 Knome Business Overview
10.4.5 Knome Recent Developments
10.5 Genomatix Software
10.5.1 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.5.2 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.5.4 Genomatix Software Business Overview
10.5.5 Genomatix Software Recent Developments
10.6 GATC Biotech
10.6.1 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.6.2 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.6.4 GATC Biotech Business Overview
10.6.5 GATC Biotech Recent Developments
10.7 Oxford Nanopore Technologies
10.7.1 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.7.2 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.7.4 Oxford Nanopore Technologies Business Overview
10.7.5 Oxford Nanopore Technologies Recent Developments
10.8 Macrogen
10.8.1 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.8.2 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.8.4 Macrogen Business Overview
10.8.5 Macrogen Recent Developments
10.9 Life Technologies
10.9.1 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.9.2 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.9.4 Life Technologies Business Overview
10.9.5 Life Technologies Recent Developments
10.10 DNASTAR
10.10.1 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.10.2 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.10.4 DNASTAR Business Overview
10.10.5 DNASTAR Recent Developments
10.11 Exosome Diagnostics
10.11.1 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.11.2 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.11.4 Exosome Diagnostics Business Overview
10.11.5 Exosome Diagnostics Recent Developments
10.12 Biomatters
10.12.1 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.12.2 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.12.4 Biomatters Business Overview
10.12.5 Biomatters Recent Developments
10.13 CLC Bio
10.13.1 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.13.2 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.13.4 CLC Bio Business Overview
10.13.5 CLC Bio Recent Developments
10.14 BGI
10.14.1 BGI Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.14.2 BGI Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.14.4 BGI Business Overview
10.14.5 BGI Recent Developments
10.15 Qiagen
10.15.1 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.15.2 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.15.4 Qiagen Business Overview
10.15.5 Qiagen Recent Developments
10.16 Perkin Elmer
10.16.1 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.16.2 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.16.4 Perkin Elmer Business Overview
10.16.5 Perkin Elmer Recent Developments
10.17 Pacific Bioscience
10.17.1 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.17.2 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.17.4 Pacific Bioscience Business Overview
10.17.5 Pacific Bioscience Recent Developments
10.18 Partek
10.18.1 Partek Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.18.2 Partek Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.18.4 Partek Business Overview
10.18.5 Partek Recent Developments
10.19 GnuBIO
10.19.1 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.19.2 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.19.4 GnuBIO Business Overview
10.19.5 GnuBIO Recent Developments
10.20 Foundation Medicine
10.20.1 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.20.2 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.20.4 Foundation Medicine Business Overview
10.20.5 Foundation Medicine Recent Developments
10.21 Paradigm
10.21.1 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.21.2 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.21.4 Paradigm Business Overview
10.21.5 Paradigm Recent Developments
10.22 Caris Life Sciences
10.22.1 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.22.2 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.22.4 Caris Life Sciences Business Overview
10.22.5 Caris Life Sciences Recent Developments
10.23 Myriad Genetics
10.23.1 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Basic Information
10.23.2 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product Overview
10.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
10.23.4 Myriad Genetics Business Overview
10.23.5 Myriad Genetics Recent Developments
11 Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Region
11.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast
11.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country
11.2.3 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Region
11.2.4 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Clinical Oncology Next Generation Sequencing (NGS) by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Clinical Oncology Next Generation Sequencing (NGS) by Type (2025-2032)
12.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Clinical Oncology Next Generation Sequencing (NGS) by Type (2025-2032)
12.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2025-2032)
12.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) Forecast by Application
12.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Clinical Oncology Next Generation Sequencing (NGS) Market Size Comparison by Region (M USD)
Table 5. Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) by Manufacturers (2019-2025)
Table 6. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing (NGS) as of 2022)
Table 10. Global Market Clinical Oncology Next Generation Sequencing (NGS) Average Price (USD/Unit) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Clinical Oncology Next Generation Sequencing (NGS) Sales Sites and Area Served
Table 12. Manufacturers Clinical Oncology Next Generation Sequencing (NGS) Product Type
Table 13. Global Clinical Oncology Next Generation Sequencing (NGS) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Clinical Oncology Next Generation Sequencing (NGS)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
Table 22. Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Type (K Units)
Table 23. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (M USD)
Table 24. Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) by Type (2019-2025)
Table 25. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2019-2025)
Table 26. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) by Type (2019-2025)
Table 27. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Share by Type (2019-2025)
Table 28. Global Clinical Oncology Next Generation Sequencing (NGS) Price (USD/Unit) by Type (2019-2025)
Table 29. Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) by Application
Table 30. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application
Table 31. Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Application (2019-2025) & (K Units)
Table 32. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2019-2025)
Table 33. Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Application (2019-2025) & (M USD)
Table 34. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2019-2025)
Table 35. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Growth Rate by Application (2019-2025)
Table 36. Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Region (2019-2025) & (K Units)
Table 37. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Region (2019-2025)
Table 38. North America Clinical Oncology Next Generation Sequencing (NGS) Sales by Country (2019-2025) & (K Units)
Table 39. Europe Clinical Oncology Next Generation Sequencing (NGS) Sales by Country (2019-2025) & (K Units)
Table 40. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales by Region (2019-2025) & (K Units)
Table 41. South America Clinical Oncology Next Generation Sequencing (NGS) Sales by Country (2019-2025) & (K Units)
Table 42. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales by Region (2019-2025) & (K Units)
Table 43. Global Clinical Oncology Next Generation Sequencing (NGS) Production (K Units) by Region (2019-2025)
Table 44. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Region (2019-2025)
Table 46. Global Clinical Oncology Next Generation Sequencing (NGS) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 47. North America Clinical Oncology Next Generation Sequencing (NGS) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 48. Europe Clinical Oncology Next Generation Sequencing (NGS) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 49. Japan Clinical Oncology Next Generation Sequencing (NGS) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 50. China Clinical Oncology Next Generation Sequencing (NGS) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2025)
Table 51. Illumina Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 52. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 53. Illumina Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 54. Illumina Business Overview
Table 55. Illumina Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
Table 56. Illumina Recent Developments
Table 57. Roche Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 58. Roche Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 59. Roche Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 60. Roche Business Overview
Table 61. Roche Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
Table 62. Roche Recent Developments
Table 63. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 64. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 65. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 66. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
Table 67. Agilent Technologies Business Overview
Table 68. Agilent Technologies Recent Developments
Table 69. Knome Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 70. Knome Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 71. Knome Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 72. Knome Business Overview
Table 73. Knome Recent Developments
Table 74. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 75. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 76. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 77. Genomatix Software Business Overview
Table 78. Genomatix Software Recent Developments
Table 79. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 80. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 81. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 82. GATC Biotech Business Overview
Table 83. GATC Biotech Recent Developments
Table 84. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 85. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 86. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 87. Oxford Nanopore Technologies Business Overview
Table 88. Oxford Nanopore Technologies Recent Developments
Table 89. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 90. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 91. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 92. Macrogen Business Overview
Table 93. Macrogen Recent Developments
Table 94. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 95. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 96. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 97. Life Technologies Business Overview
Table 98. Life Technologies Recent Developments
Table 99. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 100. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 101. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 102. DNASTAR Business Overview
Table 103. DNASTAR Recent Developments
Table 104. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 105. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 106. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 107. Exosome Diagnostics Business Overview
Table 108. Exosome Diagnostics Recent Developments
Table 109. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 110. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 111. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 112. Biomatters Business Overview
Table 113. Biomatters Recent Developments
Table 114. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 115. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 116. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 117. CLC Bio Business Overview
Table 118. CLC Bio Recent Developments
Table 119. BGI Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 120. BGI Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 121. BGI Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 122. BGI Business Overview
Table 123. BGI Recent Developments
Table 124. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 125. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 126. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 127. Qiagen Business Overview
Table 128. Qiagen Recent Developments
Table 129. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 130. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 131. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 132. Perkin Elmer Business Overview
Table 133. Perkin Elmer Recent Developments
Table 134. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 135. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 136. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 137. Pacific Bioscience Business Overview
Table 138. Pacific Bioscience Recent Developments
Table 139. Partek Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 140. Partek Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 141. Partek Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 142. Partek Business Overview
Table 143. Partek Recent Developments
Table 144. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 145. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 146. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 147. GnuBIO Business Overview
Table 148. GnuBIO Recent Developments
Table 149. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 150. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 151. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 152. Foundation Medicine Business Overview
Table 153. Foundation Medicine Recent Developments
Table 154. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 155. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 156. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 157. Paradigm Business Overview
Table 158. Paradigm Recent Developments
Table 159. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 160. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 161. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 162. Caris Life Sciences Business Overview
Table 163. Caris Life Sciences Recent Developments
Table 164. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Basic Information
Table 165. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product Overview
Table 166. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2025)
Table 167. Myriad Genetics Business Overview
Table 168. Myriad Genetics Recent Developments
Table 169. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Region (2025-2032) & (K Units)
Table 170. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Region (2025-2032) & (M USD)
Table 171. North America Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Country (2025-2032) & (K Units)
Table 172. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country (2025-2032) & (M USD)
Table 173. Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Country (2025-2032) & (K Units)
Table 174. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country (2025-2032) & (M USD)
Table 175. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Region (2025-2032) & (K Units)
Table 176. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Region (2025-2032) & (M USD)
Table 177. South America Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Country (2025-2032) & (K Units)
Table 178. South America Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country (2025-2032) & (M USD)
Table 179. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Forecast by Country (2025-2032) & (Units)
Table 180. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country (2025-2032) & (M USD)
Table 181. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Type (2025-2032) & (K Units)
Table 182. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Type (2025-2032) & (M USD)
Table 183. Global Clinical Oncology Next Generation Sequencing (NGS) Price Forecast by Type (2025-2032) & (USD/Unit)
Table 184. Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) Forecast by Application (2025-2032)
Table 185. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Clinical Oncology Next Generation Sequencing (NGS)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD), 2019-2032
Figure 5. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) (2019-2032)
Figure 6. Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country (M USD)
Figure 11. Clinical Oncology Next Generation Sequencing (NGS) Sales Share by Manufacturers in 2023
Figure 12. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Manufacturers in 2023
Figure 13. Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Clinical Oncology Next Generation Sequencing (NGS) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Clinical Oncology Next Generation Sequencing (NGS) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Type
Figure 18. Sales Market Share of Clinical Oncology Next Generation Sequencing (NGS) by Type (2019-2025)
Figure 19. Sales Market Share of Clinical Oncology Next Generation Sequencing (NGS) by Type in 2023
Figure 20. Market Size Share of Clinical Oncology Next Generation Sequencing (NGS) by Type (2019-2025)
Figure 21. Market Size Market Share of Clinical Oncology Next Generation Sequencing (NGS) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application
Figure 24. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application (2019-2025)
Figure 25. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Application in 2023
Figure 26. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2019-2025)
Figure 27. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application in 2023
Figure 28. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Growth Rate by Application (2019-2025)
Figure 29. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Region (2019-2025)
Figure 30. North America Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 31. North America Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Country in 2023
Figure 32. U.S. Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 33. Canada Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) and Growth Rate (2019-2025)
Figure 34. Mexico Clinical Oncology Next Generation Sequencing (NGS) Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 36. Europe Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Country in 2023
Figure 37. Germany Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 38. France Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 39. U.K. Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 40. Italy Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 41. Russia Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 42. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Region in 2023
Figure 44. China Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 45. Japan Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 46. South Korea Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 47. India Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 48. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 49. South America Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (K Units)
Figure 50. South America Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Country in 2023
Figure 51. Brazil Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 52. Argentina Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 53. Columbia Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 54. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 57. UAE Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 58. Egypt Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 59. Nigeria Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 60. South Africa Clinical Oncology Next Generation Sequencing (NGS) Sales and Growth Rate (2019-2025) & (K Units)
Figure 61. Global Clinical Oncology Next Generation Sequencing (NGS) Production Market Share by Region (2019-2025)
Figure 62. North America Clinical Oncology Next Generation Sequencing (NGS) Production (K Units) Growth Rate (2019-2025)
Figure 63. Europe Clinical Oncology Next Generation Sequencing (NGS) Production (K Units) Growth Rate (2019-2025)
Figure 64. Japan Clinical Oncology Next Generation Sequencing (NGS) Production (K Units) Growth Rate (2019-2025)
Figure 65. China Clinical Oncology Next Generation Sequencing (NGS) Production (K Units) Growth Rate (2019-2025)
Figure 66. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Type (2025-2032)
Figure 70. Global Clinical Oncology Next Generation Sequencing (NGS) Sales Forecast by Application (2025-2032)
Figure 71. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Application (2025-2032)
